SLC16A1 and diffuse large B-cell lymphoma: Because of the involvement of glycolysis in B-NHL progression, the targeting of lactate trafficking through the blockade of monocarboxylate transporter 1 (MCT-1) by AZD3965 shows very promising results in NHL [371], including DLBCL [372] A phase I clinical trial of AZD3965 combined to rituximab in DLBCL has recently been completed (NCT01791595) [373].